Is pre-motor diagnosis possible? The European experience

Parkinsonism and Related Disorders

Volumn 18, Issue SUPPL. 1, 2012, Pages

  Berg, Daniela ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Enriched risk cohort; Population based study; Pre motor markers; Predictive value; Progression markers

Indexed keywords

ARTICLE; CLINICAL FEATURE; EUROPEAN UNION; HUMAN; HYPOSMIA; NERVE DEGENERATION; NEUROMODULATION; NEUROPROTECTION; PARKINSON DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA;

EID: 84858661990     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/s1353-8020(11)70061-x     Document Type: Article

References (13)

1. van Nuenen BF, van Eimeren T, van der Vegt JP, Buhmann C, Klein C, Bloem BR, et al. Mapping preclinical compensation in Parkinson's disease: an imaging genomics approach. Mov Disord 2009;24(Suppl 2):S703-10.
2. Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008;63:167-73.
3. Postuma RB, Gagnon JF, Montplaisir J. Clinical prediction of Parkinson's disease: planning for the age of neuroprotection. J Neurol Neurosurg Psychiatry 2010;81: 1008-13.
4. Berg D, Seppi K, Liepelt I, Schweitzer K, Wollenweber F, Wolf B, et al. Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. Mov Disord 2010;25:1464-9.
5. Berg D. Transcranial ultrasound as a risk marker for Parkinson's disease. Mov Disord 2009;24(Suppl 2):S677-83.
6. Berg D. Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection. J Neural Transm Suppl 2006;(71):123-32.
7. Pavese N, Khan NL, Scherfler C, Cohen L, Brooks DJ, Wood NW, et al. Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study. Mov Disord 2009;24:2260-6.
8. Gasser T. Update on the genetics of Parkinson's disease. Mov Disord 2007;22(Suppl 17):S343-50.
9. Iranzo A, Valldeoriola F, Lomena F, Molinuevo JL, Serradell M, Salamero M, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2011;10:797-805.
10. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004;56:173-81.
11. Reilmann R, Bohlen S, Kirsten F, Ringelstein EB, Lange HW. Assessment of involuntary choreatic movements in Huntington's disease - Toward objective and quantitative measures. Mov Disord 2011;26:2267-73.
12. Onofrj M, Thomas A, D'Andreamatteo G, Iacono D, Luciano AL, Di Rollo A, et al. Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurol Sci 2002;23(Suppl 2):S91-4.
13. Liepelt I, Behnke S, Schweitzer K, Wolf B, Godau J, Wollenweber F, et al. Premotor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. Neurobiol Aging 2011;32:1599-606.